US Supreme Court Rejects Pharma Challenge to Medicare Drug Price Negotiation Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
- Supreme Court Ruling: The US Supreme Court declined to hear the pharmaceutical industry's challenge to the Biden administration's drug price negotiation plan, upholding lower court decisions and reinforcing the government's legal stance on controlling drug prices.
- Drug Price Negotiation Plan: This initiative aims to reduce prescription costs for Medicare beneficiaries by requiring drugmakers to negotiate maximum prices for specific medications with the Centers for Medicare & Medicaid Services, with steep daily taxes for non-compliance.
- Industry Opposition: Six companies, including Novo Nordisk and AstraZeneca, filed lawsuits claiming the plan violates the Constitution, arguing it is not a genuine negotiation but rather a government-imposed price control that could hinder innovation.
- Legal Implications: Despite multiple lawsuits, the first negotiated prices for ten drugs took effect this year, demonstrating the government's commitment to controlling drug costs, which may directly impact out-of-pocket expenses for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 230.800
Low
190.00
Averages
218.50
High
240.00
Current: 230.800
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Updates RYBREVANT Study Findings
- Survival Rate Improvement: Johnson & Johnson's CHRYSALIS-2 study reveals that the combination of RYBREVANT and LAZCLUZE achieves a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer, indicating significant potential for improving long-term patient outcomes in this challenging population.
- Consistency of Efficacy: The analysis shows consistent treatment responses across atypical EGFR mutation subgroups, including those historically linked to poorer prognoses, further validating the effectiveness and broad applicability of this therapeutic combination.
- Clinical Significance: These findings contribute to the growing evidence supporting the use of RYBREVANT plus LAZCLUZE in first-line treatment, potentially offering durable survival benefits for non-small cell lung cancer patients and driving transformative changes in clinical practice.
- Market Reaction: Despite the positive study results, JNJ's stock price fell by 2.37% to $225.33 in Friday's trading, reflecting overall market sentiment towards the biopharmaceutical sector and investor caution regarding new therapies.
See More
Walmart's Dividend Growth Amid Stock Price Decline
- Stable Dividend Growth: Walmart has increased its dividend for 53 consecutive years, demonstrating its reliability as a Dividend King, and while the dividend yield is only 0.8%, the consistent returns attract long-term investors.
- Stock Price Volatility: Despite meeting expectations for Q1 FY2027, Walmart's stock price dropped over 9% from May 20 to 26 due to a cautious outlook, reflecting market concerns over rising fuel costs impacting operations and consumer spending.
- Technology-Driven Growth: The introduction of the Walmart+ subscription plan has proven successful, with members spending four times more than non-members, and the quarterly revenue from membership fees increased by double digits, showcasing effective service transformation.
- Advertising Revenue Surge: Advertising revenue grew by 36% this quarter, becoming a significant part of Walmart's income, and combined with online sales and subscription services, it creates a sustainable revenue growth model that enhances the company's future profitability.
See More
Walmart's Dividend Opportunities Amid Stock Price Fluctuations
- Reliability of Dividend Kings: Walmart, recognized as a Dividend King, has increased its dividend for 53 consecutive years, providing a 150% return to shareholders over the past five years, showcasing its potential for stable dividends and stock price appreciation, despite a recent stock price drop of over 9% due to cautious outlook.
- Earnings Performance and Market Reaction: Walmart's fiscal 2027 Q1 results largely met expectations, but the stock price fell due to below-expectation guidance for the upcoming quarter, with investors concerned about rising fuel costs impacting distribution and consumer spending.
- Technology-Driven Growth: Walmart enhances its competitiveness through technological innovations, with the Walmart+ membership program leading to members spending four times more than non-members, and a double-digit increase in membership fee revenue this quarter, indicating strong growth potential in subscription and advertising revenue.
- Optimistic Management Outlook: Despite challenges from rising fuel costs, Walmart's management expresses optimism about future business potential, with CFO John Rainey stating that the excitement about the business is at its highest in years, reflecting confidence in sustained growth and dividend payouts.
See More
Johnson & Johnson's Lung Cancer Therapy Shows Significant Survival Improvement
- Survival Rate Data: Johnson & Johnson's RYBREVANT-LAZCLUZE combination therapy achieved a median overall survival of nearly 3.5 years in 49 patients with advanced lung cancer carrying atypical EGFR mutations, indicating the therapy's potential in treating this patient group.
- Study Results Presentation: The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; however, despite the positive data, JNJ's stock fell 2.3% during Friday trading, reflecting market caution regarding the new therapy's reception.
- Long-term Survival Rates: The data showed that 55% of patients treated with the combination were alive after three years and 46% after four years, suggesting the therapy's potential for durable disease control, which could influence future treatment decisions.
- Market Sentiment Shift: Stocktwits sentiment on JNJ improved from “neutral” to “bullish,” indicating investor optimism about the therapy's prospects, with the stock gaining over 47% in the past 12 months.
See More
RYBREVANT® and LAZCLUZE® Show Promising Results in Advanced NSCLC Treatment
- Significant Survival Improvement: In the CHRYSALIS-2 study, the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of 3.5 years in patients, significantly surpassing the two-year survival with current standard treatments, indicating the potential of this combination in difficult-to-treat non-small cell lung cancer (NSCLC) patients.
- Addressing Unmet Needs: Approximately 10-20% of EGFR mutation patients have atypical mutations, with limited effective first-line treatment options available; the dual-targeting mechanism of RYBREVANT® may provide more durable treatment outcomes for these patients, potentially reshaping treatment strategies.
- Consistent Clinical Activity: The clinical activity of RYBREVANT® plus LAZCLUZE® remained consistent across various atypical EGFR mutation subgroups, with 41% of patients continuing treatment after two years, further supporting the combination's tolerability and effectiveness.
- Favorable Safety Profile: The safety of RYBREVANT® and LAZCLUZE® combination therapy was consistent with previous reports, with most adverse events being Grade 1 or 2, and no new safety signals observed, ensuring patient safety during long-term treatment.
See More
Johnson & Johnson's RYBREVANT® and LAZCLUZE® Combination Significantly Improves Survival in NSCLC Patients
- Survival Rate Improvement: The CHRYSALIS-2 study demonstrated that the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC), indicating significant long-term efficacy in this difficult-to-treat population and potentially altering treatment paradigms.
- Objective Response Rate: The study reported a primary endpoint of a 57% objective response rate for the combination therapy, highlighting its substantial clinical activity in patients with atypical EGFR mutations and addressing the urgent market need for effective treatment options.
- Good Patient Tolerance: Among treated patients, 41% remained on RYBREVANT® for two years or longer, suggesting excellent tolerability of the treatment regimen, which may provide patients with more durable disease control.
- Significant Clinical Implications: The use of RYBREVANT® in combination with LAZCLUZE® not only targets common EGFR mutations but also extends to atypical mutations, filling a critical gap in current treatment options and indicating broad future application potential in lung cancer therapy.
See More
Johnson & Johnson Updates RYBREVANT Study Findings
- Survival Rate Improvement: Johnson & Johnson's CHRYSALIS-2 study reveals that the combination of RYBREVANT and LAZCLUZE achieves a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer, indicating significant potential for improving long-term patient outcomes in this challenging population.
- Consistency of Efficacy: The analysis shows consistent treatment responses across atypical EGFR mutation subgroups, including those historically linked to poorer prognoses, further validating the effectiveness and broad applicability of this therapeutic combination.
- Clinical Significance: These findings contribute to the growing evidence supporting the use of RYBREVANT plus LAZCLUZE in first-line treatment, potentially offering durable survival benefits for non-small cell lung cancer patients and driving transformative changes in clinical practice.
- Market Reaction: Despite the positive study results, JNJ's stock price fell by 2.37% to $225.33 in Friday's trading, reflecting overall market sentiment towards the biopharmaceutical sector and investor caution regarding new therapies.
See More
Walmart's Dividend Growth Amid Stock Price Decline
- Stable Dividend Growth: Walmart has increased its dividend for 53 consecutive years, demonstrating its reliability as a Dividend King, and while the dividend yield is only 0.8%, the consistent returns attract long-term investors.
- Stock Price Volatility: Despite meeting expectations for Q1 FY2027, Walmart's stock price dropped over 9% from May 20 to 26 due to a cautious outlook, reflecting market concerns over rising fuel costs impacting operations and consumer spending.
- Technology-Driven Growth: The introduction of the Walmart+ subscription plan has proven successful, with members spending four times more than non-members, and the quarterly revenue from membership fees increased by double digits, showcasing effective service transformation.
- Advertising Revenue Surge: Advertising revenue grew by 36% this quarter, becoming a significant part of Walmart's income, and combined with online sales and subscription services, it creates a sustainable revenue growth model that enhances the company's future profitability.
See More
Walmart's Dividend Opportunities Amid Stock Price Fluctuations
- Reliability of Dividend Kings: Walmart, recognized as a Dividend King, has increased its dividend for 53 consecutive years, providing a 150% return to shareholders over the past five years, showcasing its potential for stable dividends and stock price appreciation, despite a recent stock price drop of over 9% due to cautious outlook.
- Earnings Performance and Market Reaction: Walmart's fiscal 2027 Q1 results largely met expectations, but the stock price fell due to below-expectation guidance for the upcoming quarter, with investors concerned about rising fuel costs impacting distribution and consumer spending.
- Technology-Driven Growth: Walmart enhances its competitiveness through technological innovations, with the Walmart+ membership program leading to members spending four times more than non-members, and a double-digit increase in membership fee revenue this quarter, indicating strong growth potential in subscription and advertising revenue.
- Optimistic Management Outlook: Despite challenges from rising fuel costs, Walmart's management expresses optimism about future business potential, with CFO John Rainey stating that the excitement about the business is at its highest in years, reflecting confidence in sustained growth and dividend payouts.
See More
Johnson & Johnson's Lung Cancer Therapy Shows Significant Survival Improvement
- Survival Rate Data: Johnson & Johnson's RYBREVANT-LAZCLUZE combination therapy achieved a median overall survival of nearly 3.5 years in 49 patients with advanced lung cancer carrying atypical EGFR mutations, indicating the therapy's potential in treating this patient group.
- Study Results Presentation: The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; however, despite the positive data, JNJ's stock fell 2.3% during Friday trading, reflecting market caution regarding the new therapy's reception.
- Long-term Survival Rates: The data showed that 55% of patients treated with the combination were alive after three years and 46% after four years, suggesting the therapy's potential for durable disease control, which could influence future treatment decisions.
- Market Sentiment Shift: Stocktwits sentiment on JNJ improved from “neutral” to “bullish,” indicating investor optimism about the therapy's prospects, with the stock gaining over 47% in the past 12 months.
See More
RYBREVANT® and LAZCLUZE® Show Promising Results in Advanced NSCLC Treatment
- Significant Survival Improvement: In the CHRYSALIS-2 study, the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of 3.5 years in patients, significantly surpassing the two-year survival with current standard treatments, indicating the potential of this combination in difficult-to-treat non-small cell lung cancer (NSCLC) patients.
- Addressing Unmet Needs: Approximately 10-20% of EGFR mutation patients have atypical mutations, with limited effective first-line treatment options available; the dual-targeting mechanism of RYBREVANT® may provide more durable treatment outcomes for these patients, potentially reshaping treatment strategies.
- Consistent Clinical Activity: The clinical activity of RYBREVANT® plus LAZCLUZE® remained consistent across various atypical EGFR mutation subgroups, with 41% of patients continuing treatment after two years, further supporting the combination's tolerability and effectiveness.
- Favorable Safety Profile: The safety of RYBREVANT® and LAZCLUZE® combination therapy was consistent with previous reports, with most adverse events being Grade 1 or 2, and no new safety signals observed, ensuring patient safety during long-term treatment.
See More
Johnson & Johnson's RYBREVANT® and LAZCLUZE® Combination Significantly Improves Survival in NSCLC Patients
- Survival Rate Improvement: The CHRYSALIS-2 study demonstrated that the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC), indicating significant long-term efficacy in this difficult-to-treat population and potentially altering treatment paradigms.
- Objective Response Rate: The study reported a primary endpoint of a 57% objective response rate for the combination therapy, highlighting its substantial clinical activity in patients with atypical EGFR mutations and addressing the urgent market need for effective treatment options.
- Good Patient Tolerance: Among treated patients, 41% remained on RYBREVANT® for two years or longer, suggesting excellent tolerability of the treatment regimen, which may provide patients with more durable disease control.
- Significant Clinical Implications: The use of RYBREVANT® in combination with LAZCLUZE® not only targets common EGFR mutations but also extends to atypical mutations, filling a critical gap in current treatment options and indicating broad future application potential in lung cancer therapy.
See More
